AZD 8330

Drug Profile

AZD 8330

Alternative Names: ARRY-424704; ARRY-704; AZD8330

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Array BioPharma
  • Developer AstraZeneca
  • Class Amides; Aniline compounds; Antineoplastics; Dihydropyridines; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 30 Jun 2013 Discontinued - Phase-I for Solid tumours in USA and Norway (PO)
  • 31 Mar 2011 AstraZeneca completes its phase I trial for Solid tumours in USA and Norway (NCT00454090)
  • 14 Feb 2011 AstraZeneca completes enrolment in its phase I trial for Solid tumours in USA and Norway (NCT00454090)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top